343 related articles for article (PubMed ID: 33317398)
1. Identification of Circulating miR-762 as a Novel Diagnostic and Prognostic Biomarker for Non-Small Cell Lung Cancer.
Chen L; Li Y; Lu J
Technol Cancer Res Treat; 2020; 19():1533033820964222. PubMed ID: 33317398
[TBL] [Abstract][Full Text] [Related]
2. Downregulation of serum exosomal miR-216b predicts unfavorable prognosis in patients with non-small cell lung cancer.
Liu W; Liu J; Zhang Q; Wei L
Cancer Biomark; 2020; 27(1):113-120. PubMed ID: 31771047
[TBL] [Abstract][Full Text] [Related]
3. Low plasma miR-25 expression is a favorite prognosis factor in non-small cell lung cancer.
Zhang YL; Zhang ZL; Zhu XB; Xu L; Lu P; Xu M; Liu WJ; Zhang XY; Yao HM; Ye XW
Eur Rev Med Pharmacol Sci; 2019 Jun; 23(12):5251-5259. PubMed ID: 31298376
[TBL] [Abstract][Full Text] [Related]
4. Identification of serum miRNAs by nano-quantum dots microarray as diagnostic biomarkers for early detection of non-small cell lung cancer.
Fan L; Qi H; Teng J; Su B; Chen H; Wang C; Xia Q
Tumour Biol; 2016 Jun; 37(6):7777-84. PubMed ID: 26695145
[TBL] [Abstract][Full Text] [Related]
5. Serum miR-185 Is a Diagnostic and Prognostic Biomarker for Non-Small Cell Lung Cancer.
Liu J; Han Y; Liu X; Wei S
Technol Cancer Res Treat; 2020; 19():1533033820973276. PubMed ID: 33251978
[TBL] [Abstract][Full Text] [Related]
6. Evaluating the diagnostic and prognostic value of serum miR-770 in non-small cell lung cancer.
Sun B; Liu HF; Ding Y; Li Z
Eur Rev Med Pharmacol Sci; 2018 May; 22(10):3061-3066. PubMed ID: 29863251
[TBL] [Abstract][Full Text] [Related]
7. Upregulation of serum miR-494 predicts poor prognosis in non-small cell lung cancer patients.
Zhang J; Wang T; Zhang Y; Wang H; Wu Y; Liu K; Pei C
Cancer Biomark; 2018; 21(4):763-768. PubMed ID: 29286916
[TBL] [Abstract][Full Text] [Related]
8. Circulating long non-coding RNA AFAP1-AS1 is a potential diagnostic biomarker for non-small cell lung cancer.
Li W; Li N; Kang X; Shi K
Clin Chim Acta; 2017 Dec; 475():152-156. PubMed ID: 29080690
[TBL] [Abstract][Full Text] [Related]
9. Serum exosomal miR-378 upregulation is associated with poor prognosis in non-small-cell lung cancer patients.
Zhang Y; Xu H
J Clin Lab Anal; 2020 Jun; 34(6):e23237. PubMed ID: 32061007
[TBL] [Abstract][Full Text] [Related]
10. Diagnostic Value of Serum miR-182, miR-183, miR-210, and miR-126 Levels in Patients with Early-Stage Non-Small Cell Lung Cancer.
Zhu W; Zhou K; Zha Y; Chen D; He J; Ma H; Liu X; Le H; Zhang Y
PLoS One; 2016; 11(4):e0153046. PubMed ID: 27093275
[TBL] [Abstract][Full Text] [Related]
11. Decreased expression of miR-204 in plasma is associated with a poor prognosis in patients with non-small cell lung cancer.
Guo W; Zhang Y; Zhang Y; Shi Y; Xi J; Fan H; Xu S
Int J Mol Med; 2015 Dec; 36(6):1720-6. PubMed ID: 26497897
[TBL] [Abstract][Full Text] [Related]
12. Low serum miR-98 as an unfavorable prognostic biomarker in patients with non-small cell lung cancer.
Wang K; Dong L; Fang Q; Xia H; Hou X
Cancer Biomark; 2017 Sep; 20(3):283-288. PubMed ID: 28946561
[TBL] [Abstract][Full Text] [Related]
13. Folate Receptor-Positive Circulating Tumor Cell Detected by LT-PCR-Based Method as a Diagnostic Biomarker for Non-Small-Cell Lung Cancer.
Chen X; Zhou F; Li X; Yang G; Zhang L; Ren S; Zhao C; Deng Q; Li W; Gao G; Li A; Zhou C
J Thorac Oncol; 2015 Aug; 10(8):1163-71. PubMed ID: 26200270
[TBL] [Abstract][Full Text] [Related]
14. High preoperative and postoperative levels of carcinoembryonic antigen and CYFRA 21-1 indicate poor prognosis in patients with pathological Stage I nonsmall cell lung cancer.
Duan X; Cui Y; Li H; Shi G; Wu B; Liu M; Chang D; Wang T; Kong Y
Indian J Cancer; 2015 Dec; 52 Suppl 3():E158-63. PubMed ID: 27453414
[TBL] [Abstract][Full Text] [Related]
15. The relationship between Glasgow Prognostic Score and serum tumor markers in patients with advanced non-small cell lung cancer.
Jiang AG; Chen HL; Lu HY
BMC Cancer; 2015 May; 15():386. PubMed ID: 25956656
[TBL] [Abstract][Full Text] [Related]
16. Investigation of serum miR-411 as a diagnosis and prognosis biomarker for non-small cell lung cancer.
Wang SY; Li Y; Jiang YS; Li RZ
Eur Rev Med Pharmacol Sci; 2017 Sep; 21(18):4092-4097. PubMed ID: 29028091
[TBL] [Abstract][Full Text] [Related]
17. Serum microRNA-365 in combination with its target gene TTF-1 as a non-invasive prognostic marker for non-small cell lung cancer.
Liu Y; Zhang G; Li H; Han L; Fu A; Zhang N; Zheng Y
Biomed Pharmacother; 2015 Oct; 75():185-90. PubMed ID: 26337230
[TBL] [Abstract][Full Text] [Related]
18. The Role of Change Rates of CYFRA21-1 and CEA in Predicting Chemotherapy Efficacy for Non-Small-Cell Lung Cancer.
Zhao T; Mao G; Chen M
Comput Math Methods Med; 2021; 2021():1951364. PubMed ID: 34603482
[TBL] [Abstract][Full Text] [Related]
19. Combination of serum miRNAs with Cyfra21-1 for the diagnosis of non-small cell lung cancer.
Zhou C; Chen Z; Dong J; Li J; Shi X; Sun N; Luo M; Zhou F; Tan F; He J
Cancer Lett; 2015 Oct; 367(2):138-46. PubMed ID: 26213369
[TBL] [Abstract][Full Text] [Related]
20. Clinical significance of serum miR-25 in non-small-cell lung cancer.
Li J; Yu M; Liu Z; Liu B
Br J Biomed Sci; 2019 Jul; 76(3):111-116. PubMed ID: 30919763
[No Abstract] [Full Text] [Related]
[Next] [New Search]
